The Canadian Agency for Drugs and Technologies in Health (CADTH) has received a request for advice for denosumab (Prolia®). The request for advice comes from their participating drug plans, and can result in a revised Canadian Drug Expert Committee (CDEC) recommendation or a CDEC Record of Advice.
CADTH is interested in learning:
- How should fracture risk be best described?
- Is there a place for age (>75 years) or bone density scores, or are these adequately captured within fracture risk?
- How should bisphosphonate failure be best described?
- How should bisphosphonate intolerance be best described?